4-Bromo-2-fluoro-5-methylbenzonitrile, 95.0%, 250mg

4-Pyrrolidin-1-yl-butyric acid hydrochloride, 95.0%, 5g

6-Iodo-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, 98%, 250mg

2-Tetrazol-1-yl-benzoic acid, 95.0%, 1g

6-(BENZYLOXY)-5-METHYLPYRROLO[1,2-F][1,2,4]TRIAZIN-4(3H)-ONE, 95.0%, 250mg

(R)-4-Phenylthiazolidine-2-thione>98.0%(GC)1g

2-((4-Chloro-2-nitrophenyl)amino)benzoic acid, 95.0%, 5g

Ethyl 4-amino-6-chloro-5-fluoronicotinate, 97%, 5g

Methyl 2-amino-3-formylbenzoate, 95+%, 5g

2-methyl-2-(4-morpholinyl)-1-propanol, 95.0%, 5g

8-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2(1H)-one, 95+%, 250mg

Phase contrast slide with phase rings for PLPH 20x and S100x oil plan phase objectives

2-Methylsulfonyl-1-[6-(trifluoromethyl)pyridin-3-yl]ethanone, 97.0%, 5g